(BCAT) BlackRock Capital - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260U1097

Bonds, Stocks, Alternatives

BCAT EPS (Earnings per Share)

EPS (Earnings per Share) of BCAT over the last years for every Quarter: "2021-06": 1.39, "2021-12": -0.31, "2022-06": -3.06, "2022-12": 0.15, "2025-06": null,

BCAT Revenue

Revenue of BCAT over the last years for every Quarter: 2021-06: null, 2021-12: null, 2022-06: null, 2022-12: null, 2025-06: null,

Description: BCAT BlackRock Capital

BlackRock Capital Allocation Trust (BCAT) is a closed-end investment company listed on the NYSE, operating within the Asset Management & Custody Banks sub-industry. Its primary objective is to provide shareholders with a high level of income and capital appreciation.

The trusts performance is closely tied to the overall health of the financial markets, particularly the asset management sector. Key economic drivers influencing BCATs performance include interest rates, market volatility, and the overall demand for asset management services. The trusts ability to generate income is also affected by the dividend yield of its underlying investments.

To evaluate BCATs performance, key performance indicators (KPIs) such as the distribution yield, net asset value (NAV) return, and the trusts expense ratio are crucial. A high distribution yield indicates a strong income generation capability, while a stable NAV return suggests effective investment management. A low expense ratio is also desirable as it maximizes the returns to shareholders.

The asset management industry is highly competitive, with firms like BlackRock, Vanguard, and State Street Global Advisors dominating the market. BCATs ability to compete effectively is influenced by its investment strategy, the expertise of its management team, and its ability to adapt to changing market conditions.

From a financial perspective, BCATs market capitalization and price-to-earnings (P/E) ratio are important metrics. A relatively low P/E ratio may indicate undervaluation, presenting a potential buying opportunity. The trusts return on equity (RoE) is also a critical metric, as it measures the return generated on shareholders equity.

BCAT Stock Overview

Market Cap in USD 1,550m
Sub-Industry Asset Management & Custody Banks
IPO / Inception 2020-09-25

BCAT Stock Ratings

Growth Rating 41.7%
Fundamental 51.2%
Dividend Rating 94.3%
Return 12m vs S&P 500 -2.32%
Analyst Rating -

BCAT Dividends

Dividend Yield 12m 23.77%
Yield on Cost 5y 29.86%
Annual Growth 5y 91.11%
Payout Consistency 82.5%
Payout Ratio 153.5%

BCAT Growth Ratios

Growth Correlation 3m 85.8%
Growth Correlation 12m 67.4%
Growth Correlation 5y 35.7%
CAGR 5y 5.77%
CAGR/Max DD 5y 0.16
Sharpe Ratio 12m 0.87
Alpha 4.94
Beta 0.499
Volatility 11.24%
Current Volume 679.3k
Average Volume 20d 551.5k
Stop Loss 14.5 (-3.5%)
Signal 1.06

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (194.4m TTM) > 0 and > 6% of Revenue (6% = 11.9m TTM)
FCFTA 0.18 (>2.0%) and ΔFCFTA 10.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA 0.18 (>3.0%) and CFO 354.9m > Net Income 194.4m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
error: Current Ratio cannot be calculated (needs Total Current Assets and Liabilities)
Outstanding Shares last Quarter (NaN) change vs 12m ago NaN% (target <= -2.0% for YES)
Gross Margin 98.35% (prev 0.0%; Δ 98.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 9.46% (prev 9.18%; Δ 0.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.0 (EBITDA TTM 0.0 / Interest Expense TTM 1.40m) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 51.21

1. Piotroski 4.0pt = -1.0
2. FCF Yield 22.99% = 5.0
3. FCF Margin data missing
4. Debt/Equity data missing
5. Debt/Ebitda data missing
6. ROIC - WACC 0.0% = 0.0
7. RoE 10.60% = 0.88
8. Revenue Trend data missing
9. Revenue CAGR data missing
10. EPS Trend -46.77% = -1.17
11. EPS CAGR -94.86% = -2.50

What is the price of BCAT shares?

As of August 30, 2025, the stock is trading at USD 15.03 with a total of 679,312 shares traded.
Over the past week, the price has changed by +1.42%, over one month by +2.03%, over three months by +7.35% and over the past year by +14.25%.

Is BlackRock Capital a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, BlackRock Capital is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 51.21 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCAT is around 19.91 USD . This means that BCAT is currently undervalued and has a potential upside of +32.47% (Margin of Safety).

Is BCAT a buy, sell or hold?

BlackRock Capital has no consensus analysts rating.

What are the forecasts/targets for the BCAT price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 22.1 46.8%

Last update: 2025-08-28 04:33

BCAT Fundamental Data Overview

Market Cap USD = 1.55b (1.55b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 6.30m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 8.082
P/S = 7.9489
P/B = 0.9003
Beta = None
Revenue TTM = 197.7m USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -6.30m USD (from netDebt column, last quarter)
Enterprise Value = 1.54b USD (1.55b + (null Debt) - CCE 6.30m)
Interest Coverage Ratio = 0.0 (Ebit TTM 0.0 / Interest Expense TTM 1.40m)
FCF Yield = 22.99% (FCF TTM 354.9m / Enterprise Value 1.54b)
FCF Margin = 179.5% (FCF TTM 354.9m / Revenue TTM 197.7m)
Net Margin = 98.35% (Net Income TTM 194.4m / Revenue TTM 197.7m)
Gross Margin = 98.35% ((Revenue TTM 197.7m - Cost of Revenue TTM 3.25m) / Revenue TTM)
Tobins Q-Ratio = 0.90 (Enterprise Value 1.54b / Book Value Of Equity 1.72b)
Interest Expense / Debt = unknown (Interest Expense 1.40m / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets 6.30m / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt -6.30m / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 354.9m)
Total Stockholder Equity = 1.83b (last 4 quarters mean)
RoA = 10.10% (Net Income 194.4m, Total Assets 1.92b )
RoE = 10.60% (Net Income TTM 194.4m / Total Stockholder Equity 1.83b)
RoCE = unknown (Ebit 0.0 / (Equity 1.83b + L.T.Debt none))
RoIC = 0.0% (NOPAT 0.0 / Invested Capital 1.87b)
WACC = unknown (E(1.55b)/V(0.0) * Re(7.85%)) + (D(none)/V(0.0) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 5.10 | Cagr: 1.82%
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈285.5m ; Y1≈352.2m ; Y5≈600.8m
Fair Price DCF = 97.53 (DCF Value 10.22b / Shares Outstanding 104.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -46.77 | EPS CAGR: -94.86%
EPS Growth-of-Growth: N/A

Additional Sources for BCAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle